$ELVN insider trading

Over the last 12 months, Enliven Therapeutics insiders reported no purchases and 9 sales totaling $63.2M across SEC Form 4 filings. 78% of the activity was filed under pre-arranged 10b5-1 trading plans.

$63.2M
9
5
78%
Side
$100K$1.0M$10M$100MJun '26JulAug
Collins Helen Louise
Hohl Benjamin
Kunkel Lori Anne
ORBIMED ADVISORS LLC
Derynck Mika K

All insider trades

Aug 4, 2026Derynck Mika K▼ Sale158,795$60.21$9.6M-100%
Jul 17, 2026Hohl Benjamin▼ Sale6,018$52.64$317K-11.6%
Jul 17, 2026Collins Helen Louise▼ Sale5,000$52.67$263K-16.7%
Jul 6, 2026Kunkel Lori Anne▼ Sale10,000$50.49$505K-19.3%
Jun 22, 2026ORBIMED ADVISORS LLC▼ Sale860,123$45.36$39.0M-11.6%
Jun 17, 2026Hohl Benjamin▼ Sale6,018$43.8$264K-10.6%
Jun 17, 2026Collins Helen Louise▼ Sale5,000$43.8$219K-16.7%
Jun 15, 2026ORBIMED ADVISORS LLC▼ Sale281,408$45.02$12.7M-3.7%
Jun 5, 2026Kunkel Lori Anne▼ Sale10,000$34.54$345K-16.2%

Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ELVN feed.

ELVN Insider Trading — Form 4 Buys & Sells | alphai